logo

MCRB

Seres Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.56 / 10
Netural

Money flow analysis registers 7.65/10, indicating robust fund inflows despite a negative overall trend in block and medium-size flows. This healthy cash entry may support price stabilization. Analyst coverage is minimal (one opinion) but uniformly Strong Buy, aligning with the positive sentiment in fund flows; however, the scarcity of analyst views limits conviction. Together, the data present a neutral-to-positive bias from the flow and sentiment side, contrasting with the weak technicals.

FundamentalSentiment(5.56)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-09-24
InstitutionCanaccord Genuity
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for MCRB?
  • MCRB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.56/10 (Netural).